Xiao Han

Ms. Xiao Han


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2023 in Journal of Cardiovascular Pharmacology
Verified
Journal Article
Open access
XZXinxin Zhang
Xinxin Zhang
NWNing Mm Wang
Ning Mm Wang
PFPeng Mm Fu
Peng Mm Fu
YAYanliang Mm An
Yanliang Mm An
FSFangfang Msc Sun
Fangfang Msc Sun
YLYing Liu
Ying Liu
Heart failure with preserved ejection fraction (HFpEF) is highly prevalent, accounting for 50% of all heart failure patients, and is associated with significant mortality. Sodium–glucose cotransporter subtype inhibitor (SGLT2i) is recommended in the AHA and ESC guidelines for the treatment of HFpEF, but the mechanism of SGLT2i to prevent and treat cardiac remodeling and dysfunction is currently unknown, hindering the understanding of the pathophysiology of HFpEF and the development of novel therapeutics. HFpEF model was induced by a high-fat diet (60% calories from lard) + N[w]-nitro-l-arginine methyl ester (l-NAME—0.5 g/L) (2 Hit) in male Sprague Dawley rats to effectively recapture the myriad phenotype of HFpEF. This study's results showed that administration of dapagliflozin (DAPA, SGLT2 inhibitor) significantly limited the 2-Hit–induced cardiomyocyte hypertrophy, apoptosis, inflammation, oxidative stress, and fibrosis. It also improved cardiac diastolic and systolic dysfunction in a late-stage progression of HFpEF. Mechanistically, DAPA influences energy metabolism associated with fatty acid intake and mitochondrial dysfunction in HFpEF by increasing β-hydroxybutyric acid (β-OHB) levels, directing the activation of citrate synthase, reducing acetyl coenzyme A (acetyl-CoA) pools, modulating adenosine 5′-triphosphate production, and increasing the expression of mitochondrial oxidative phosphorylation system complexes I-V. In addition, following clinical DAPA therapy, the blood levels of β-OHB and citrate synthase increased and the levels of acetyl-CoA in the blood of HFpEF patients decreased. SGLT2i plays a beneficial role in the prevention and treatment of cardiac remodeling and dysfunction in HFpEF model by attenuating cardiometabolic dysregulation.

1 January 2022 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
YZYUNLONG ZHANG
YUNLONG ZHANG
BZBo Zhang
Bo Zhang
XHXiao Han
Xiao Han
BZBo Zhang
Bo Zhang
HLHuihua Li
Huihua Li
Myocardial ischemia/reperfusion injury (I/RI) is closely associated with energy substrate metabolism. Fibronectin 1 (Fn1) was markedly elevated in the heart of I/R pigs and ischemic patients, but its role in myocardial I/RI is controversial and the precise mechanism involved remains elusive. Herein, we tested whether blockage of Fn1 with its inhibitor (fibronectin tetrapeptide, RGDS) would alleviate myocardial I/RI. Wild‐type (WT) mice were administered with RGDS once 3 h before I/R operation and once at 24 or 48 h postreperfusion, and sacrificed at 24 or 72 h post‐I/R, respectively. Cardiac function was evaluated by echocardiography. Myocardial infarction size, apoptosis, fibrosis, and inflammation were examined via histological staining. Uptake of glucose and fatty acids were detected by positron emission tomography (PET) and computer tomography (CT) with [18F]‐2‐fluoro‐2‐deoxy‐D‐glucose (FDG) and [18F]‐fluoro‐6‐thia‐heptadecanoic acid (FTHA), respectively. Our results showed that administration of RGDS to mice remarkably limited the I/R‐induced myocardial infarct size, myocyte apoptosis, inflammation, oxidative stress, and fibrosis and improved cardiac contractile dysfunction. These protective effects were associated with upregulation of the AMP/ATP ratio and the activation of LKB1‐AMPK signaling, which subsequently increased AS160‐GLUT4‐mediated glucose and fatty acid uptake, improved mitochondrial dynamic imbalance, and inactivated TGF‐β and NF‐κB signals in the I/R heart. In conclusion, the current study identified that blocking Fn1 protects against myocardial I/RI likely through activating the LKB1‐AMPK‐dependent signals and highlights that inhibition of Fn1 may be a novel therapeutic option for treating ischemic heart diseases.

14 August 2025 in Clinical Science
Verified
Journal Article
Open access
CLChao Li
Chao Li
XHXiao Han
Xiao Han
JHJiakang He
Jiakang He
STSheng-Xing Tang
Sheng-Xing Tang
YZYUNLONG ZHANG
YUNLONG ZHANG
LGLianjun Gao
Lianjun Gao
Heart failure with preserved ejection fraction (HFpEF) represents the initial phase of cardiac dysfunction associated with type 2 diabetes mellitus (T2DM). To date, the pathophysiological mechanisms underlying T2DM-induced HFpEF are complex and elusive. Fibroblast activation protein (FAP) is a prolyl-specific serine protease that its inhibition or vaccination has been shown to enhance cardiac repair following myocardial infarction (MI). However, the role and underlying molecular mechanisms by which abnormal FAP activity promotes the development of T2DM-induced HFpEF remain to be elucidated. In this study, the plasma activity and level of FAP were significantly higher in the T2DM with HFpEF group compared to the healthy control group. Moreover, plasma FAP activity and level were positively correlated with the likelihood of T2DM with HFpEF. To investigate the mechanistic involvement of FAP in the development of T2DM-associated HFpEF, a chronic T2DM mouse model was established. The results revealed that FAP KO significantly improved BNP level and E/A ratios compared to the WT T2DM group. Additionally, FAP KO and FAP inhibitor Talabostat alleviated myocardial inflammation, fibrosis, cardiomyocyte apoptosis, oxidative stress and energy metabolism dysfunction. Mechanistically, abnormal increase FAP triggered the CaMKIIδ-Calcineurin A-NFATc2 signaling pathway, leading to the aforementioned pathological changes in T2DM-induced HFpEF. In contrast, FAP KO suppressed the CaMKIIδ-Calcineurin A-NFATc2 signaling pathway and attenuated these pathological changes. Overall, these findings suggest that FAP may serve as a critical therapeutic target for T2DM-induced HFpEF.

19 August 2025 in Journal of Molecular Medicine
Verified
Journal Article
Closed access
PDF file
YZYun-Long Zhang
Yun-Long Zhang
ZXZe-Yan Xu
Ze-Yan Xu
YSYan Sun
Yan Sun
QZQian-Qiu Zhu
Qian-Qiu Zhu
STSheng-Xing Tang
Sheng-Xing Tang
XHXiao Han
Xiao Han

5 May 2026 in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Verified
Journal Article
Open access
YZYUNLONG ZHANG
YUNLONG ZHANG
TCTang-Na Chen
Tang-Na Chen
JHJia-Kang He
Jia-Kang He
YZYue Zhu
Yue Zhu
XWXiang-Hai Wang
Xiang-Hai Wang
XHXiao Han
Xiao Han
Atrial fibrillation (AF), the most prevalent form of cardiac arrhythmia, frequently develops as a complication of acute myocardial infarction (MI). Nonetheless, the temporal dynamics of gene expression and key signaling pathways implicated in the development of AF following MI remain elusive. Male wild-type C57BL/6 mice were subjected to coronary artery ligation to induce MI for 1, 3, or 7 days. AF inducibility, atrial diameter, and pathological alterations were examined using programmed intracardiac stimulation, echocardiography, and histological staining. Temporal gene expression profiles were analyzed via microarray analysis. A total of 3364 differentially expressed genes (DEGs) were identified in atrial tissues at 1, 3, and 7 days post-MI compared to sham controls. These DEGs were primarily associated with mitochondrial function and the citrate cycle (TCA cycle) in atrial tissues following MI. Furthermore, co-expression network analysis revealed that APAF1-interacting protein (APIP) was centrally positioned in the gene co-expression network. Moreover, its expression was significantly downregulated in atrial tissues across various time points following MI. Cardiomyocyte-specific overexpression of APIP significantly attenuated atrial remodeling and fibrillation following MI. These beneficial effects were accompanied by elevated Mfn1/Mfn2 and p-Drp1(S637) levels, reduced Drp1 expression levels, and enhanced mitochondrial function. Finally, APIP upregulated citrate synthase (CS), enhanced respiratory complexes I-V, and significantly increased ATP synthesis. This study systematically characterized temporal changes in differentially expressed genes (DEGs) associated with AF following MI and highlights the protective role of APIP in mitigating AF development post-MI, positioning it as a therapeutic target for AF management.